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ESSAY: PHARMACEUTICALS AND GLOBAL JUSTICE: BALANCING PUBLIC HEALTH
AND INTELLECTUAL PROPERTY RIGHTS
by Marisa Morabito
I. INTRODUCTION
Patents and prices have had a detrimental impact on poverty and the spread of diseases
such as HIV/AIDS which remains a significant issue globally, especially in South Africa.
Hopkins states "The Agreement on Trade Related Aspects of Intellectual Property Rights
(TRIPS), govemed by the World Trade Organization, provides for stringent patent protection in
the name of intellectual property rights. This international agreement has elicited public health
concerns in developing countries, worried that they will be unable to access essential medicines
as a result of increasing patented drug costs."l According to statistics from the Just Like My
Child Foundation, HIV/AIDs in Africa are great in number.2 Statistics show that "to date, 17
million Africans have died of AIDS and 25 million Africans (many children) are infected with
the HIV virus. HIV can be treated with modern medications, so long as those drugs are available
and administered."3 Statistics have shown that "18 million deaths per year 
- 
50 thousand daily-
are due to preventable poverty related causes...while one-third of the world's population subsists
on less than $2 per day and half of the world's population in some of the poorest countries in
Asia and Africa lack access to essential medicines."4 Globally, there has been a constant
struggle in balancing intellectual property rights with human health and poverty reduction.
Crook reports that "the Joint LIN Program on HIV/AIDS estimates that between thirty-four and
forty-six million people around the world are living with the condition."
I Victoria E. Hopkins, Analysis of International Patent Protection and Global Public Health at 83,
http://www.princeton.edu/jpia/past-issues- 1 /2006/5.pdf.
2 Just Like My Child Foundation, HIV/AIDs at l. 2010.
3 Just Like My Child Foundation, HIV/AIDs at l.
a Hopkins at 85-86.
While sub-Saharan African states have suffered the worst epidemics to date, the World
Health Organization (WHO) predicts new outbreaks in North Africa, India, China, states in
Central Asia, and the Baltic states."5 Crook describes that "anti-retroviral drugs do not reach the
90% of HIV/AIDS infected people living in the poorest 10% of the world's countries. In South
Africa, tens ofthousands ofpeople are dying every year because excessive prices are charged for
life-saving antiretroviral medicines. The worst is probably yet to come for South Africa, where
lack ofaccess to effective medication will facilitate the rapid spread of AIDS-related deaths."6
In South Africa, the Medicines Act was established in order for actions to be taken in
order to promote public health in times of severe need, such as allowing for compulsory
licensing. However, countries such as the United States have prevented this Act from being used
to accomplish its purpose.i For instance, the United States responded that the South Africa
Medicines Act would violate IP rights and impact the economy by adversely affecting
pharmaceutical companies.8 Hopkins states that "The heart of the debate is striking a balance
between the rights to IP protection, championed by multinationals and developed countries, and
the developing world's right to health via affordable drugs in the face of extreme disease and
poverty."e
The above outlined consequences of the prevailing policies regarding IP protection and
pharmaceuticals is a result of a utilitarian economics approach. The utilitarian economics
approach and the approach which pharmaceutical companies have expressed is that there is a
need for strong patent protection in order to generate profits which will allow pharmaceutical
5 Jamie Crook, Balancing Intellectual Property Protection with the Human Right to Health at 524.
6 Crook at 525.
7 Nagan, Intemational Intellectual Property, Access to Health Care, and Human Rights: South Afiica v. United
States. Florida lournal oflntemational Law at l'18.2002.
8 Nagan at 178.
e Hopins at 84.
companies to further their research and innovation of medical drugs which will consequently be
better for global health. For instance, utilitarian economic theory is based on the belief that there
should be strong IP rights which are strongly enforced against those who infringe in order to
incentivize people to innovate.l0 Utilitarian economics is based on the premise that incentives
will allow for a high amount of social goods.ll The utilitarian approach is based upon the
premise that the creation and distribution of effective pharmaceutical products requires
motivated individuals. In the absence of motivated individuals there will be no innovation and
widespread distribution of critical pharmaceutical products. Therefore, the public good will not
be served. Utilitarians want to protect scientific innovation as they believe that a lack of
protection through the use of IP rights would cause there to be no incentive since others could
pirate their inventions and products and profit without actually creating it.l2 Utilitarians want to
achieve the highest overall well-being and since pharmaceuticals will allow for the welfare of
humans, IP rights and patents are necessary to protect their inventions and products of the
inventors.13 The evidence suggests however, that the continued policy of IP rights as manifested
in TRIPS does not result in the greatest good for the greatest number of people but even further
is unjust and therefore morally wrong. The utilitarian approach has been deemed unjust. This is
because the struggle with poverty has continued to have devastating impacts due to
pharmaceutical companies who have charged excessive prices and fail to allow generic drugs to
treat illnesses, including anti-retrovirals in order to treat HIV/AIDS.
r0 An Alternative to Intellectual Property Theories of Locke and Utilitarian Economics, Michael Morrissey at 17,
http://etd.lsu.edu/docs/available/etd-07032012-160303/unrestricted/morrisseythesis.pdf.
lr Morrissey at 17.
12 The Clash between Global Justice and Pharmaceutical Patents: Cernea and Uszkai at215-216,
file:///C:/Users/morabima/Downloads/the-clash-between-global-justice-and-drug-patents-a-critical-analysis.pdf.
13 Cernea and Uszkai at215-216.
The approach to IP rights and global pharmaceutical industry thus requires a different
philosophical, ethical framework. I would like to suggest a virtue and human flourishing
approach which is based on human good and well-being and helping others to also be able to
flourish by living ethical lives which parallels Nussbaum's capabilities approach, a virtue ethics
view.la Virtue ethics is an ethical system based upon adherence to a principle. Virtue ethicists
believe that there are "certain ideals toward which we should strive...[to allow] for the full
development of our humanity" by looking at what humans can become.ls The virtue ethicist
focuses on humans achieving their maximum potential while having virtues of compassion,
generosity and courage.l6 For instance, "a person who has developed virtues will be naturally
disposed to act in ways consistent with moral principles.lT Virtue ethics emphasizes character
formation and habits to foster positive improvements in the world.18 A virtuous person wants to
behave well and looks at a circumstance and decides what is right and wishes to behave
according to what is right.le This view aligns with Nussbaum who takes a capabilities view
which is based on the idea that well-being is "of vital moral importance [and]... individuals must
have real opportunities to live well and to flourish as human beings.20 Nussbaum's capabilities
view looks at the important functions of a human being and looks at what institutions are doing
for those capabilities.2r For example, functions and capabilities are set and then we observe
whether intuitions are promoting human flourishing based on these principles.22 If the standards
Ia Morrissey at 47.
15 Thinking Ethically: A Framework for Moral Decision Making, Manuel Velasquez at l,
http://www.scu.edu/ethics/practicing/decisioMhinkine.html/.
16 Velasquez at l.
17 A virtue ethics approach to moral dilemmas in medicine, P Gardiner at l,
http://jme.bmj.com/c ontentl 29 / 5 /297.1ong.
rE Velasquez at 2.
re Gardiner at l.
20 Morrissey at 47.
2r Morrissey at 47.
22 Morrissey at 48.
are not being met, we must try to change the institution's policies to allow for human
flourishing.23 Nussbaum's capabilities approach explains what flourishing is and tries to achieve
this flourishing worldwide.2a Based on this theory, IP rights "generate a material circumstance
for a majority of the world in which we can't maximally exercise our intellectual capacities, and
thus we fail as a species to maximally flourish."25 Therefore any further discussion of IP rights
and the global pharmaceutical industry must proceed clearly focused on adherence to a moral
principle; maximizing human flourishing.
Successful efforts in South Africa were only achieved when the policy became
virtue/principle based. In the Minister of Health v. Treatment Action Campaign, the court ruled
that the government breached the people's right to have access to health care services when it
prevented drug availability to pregnant women in order to stop mother-to-child HIV
transmission.26 2.4 million people have received free anti-retroviral treatment in 2013 which was
a 1.4 million increase from 2009 while over 20 million people have been tested for HIV since the
government created counseling and testing programs in2010.27 South Africa's goal is to have an
extra 4.6 million people receiving anti-retroviral treatment within the next five years.28
Furthermore, South Africa has reduced the prices of anti-retrovirals and there was a tender to
make one ARV pill which can be used once instead of having to take three pills two times per
day which means there will be fewer pills used and consumed.2e Although there have been
23 Morrissey at 48.
2a Morrissey at 48.
25 Morrissey at 48.
26 Zivi at 180.
27 SA to expand HIV treatment program, 2014 at l,
http://www.southafrica.info/about/government/stateofrtation20l4e.htm#.UwN24P6A0eE.
28 SA to expand HIV treatment program at L
2e South Africa's savings in procurement of antiretroviral drugs at 1,2012,
http://www.unaids.org/enlresources/presscentre/featurestories/2012lnovember/20l21l3Dzatreatmentprices/.
successes, the South African population continues to have the highest number of HIV/AIDS
infected people globally as millions still lack access to ARVs.30
The ongoing tension between the fight against poverty and IP rights continues to persist
at the mercy of humans in poorer nations who are unable to afford medications to cure their
illnesses and diseases which hinders maximum human flourishing and does not express good
character. In her article "Common Ground: The Case for Collaboration Between Anti-Poverty
Advocates and Public Interest Intellectual Property Advocates" Cantrell states that with
intellectual property advocates, their focus is on the individuals rights to create, appropriate, and
recreate.3l However, the tension between the fight against poverty and the protection of
intellectual property rights is evident as the IP movement's success is frequently at the expense
of the poor.32 Cantrell continues to state that Martha Nussbaum's virtue theory of human
capabilities suggests that every person should have the ability to live a flourishing life yet the IP
movement has placed limitations on what a person can do and be as a result of continued
poverty.33
Advocates of the anti-poverty movement have placed significant emphasis on the United
Nations Commission on Human Rights which has determined that access to medicine is a human
right.3a However, pharmaceutical companies have a great amount of control over the distribution
and prices of medications. For instance, the World Trade Organization implemented TRIPS, an
intemational treaty regarding intellectual property rights standards in order to allow for IP
protection.35 The idea behind the TRIPS treaty was to give pharmaceutical companies an
30 7.ivi at 182.
3r Deborah I. Cantrell, Common Ground: The Case for Collaboration Between Anti-Poverty Advocates and Public
Interest Intellectual Property Advocates, Spring 2008 at 423.
32 Cantrell at 423.
13 Cantrell at 428.
3a Universal Declaration ofHuman Rights, available at http://www.un.org/Overview/rights.html.
35 Crook at 530.
incentive to invent medications while being able to profit from the creation of pharmaceutical
drugs. TRIPS provides for patent protection for twenty years from the time of filing.36
Proponents of intellectual property rights including intellectual property specialist Gerald
Mossinghoff have explained :
"Effective patent protection at home and abroad is vitally important to the United States
pharmaceutical industry. America's research-based pharmaceutical companies pour millions of
dollars into the research and development of new technology every year. Whether this
commitment can continue depends greatly upon the extent to which foreign govemments allow
innovators to be rewarded for their inventiveness, monetary investment, and intellectual labor.
For the private sector pharmaceutical industry, which has been the primary source of new
therapies for the past four decades, there is little incentive to provide an ever-increasing
commitment to research unless there are reasonable expectations of financial retum. Only
effective patent protection provides the incentives necessary to enable pharmaceutical companies
to commit the required resources."
IP rights proponents have argued that protection is essential for incentives to create.37
Furthermore, Hopkins explains additional arguments in favor of IP protection are the incentives
due to the financial rewards as a lack of patents would make it hard for creators to recover their
investments due to reverse engineering and knock offs which would result in fewer investments
and less research to treat worldwide diseases.3s
However, this patent protection inflates prices more than one hundred times their cost
which hinders humans worldwide fiom opportunity and from being able to have well-being so
36 Lazzarini at 109.
37 Fisher and Syed at 6?2.
38 Hopkins at 85.
that they may flourish.3e It is significant to note the political power that pharmaceutical
companies, especially in the United States, where lobbyists contributed millions annually.
Although innovators should be rewarded, pharmaceutical companies should shift their focus to
poorer nations in order to limit the spread of disease, allow those in poverty right to life and
result in more trading partners by having a pricing scheme based on per capita income in order to
allow medications and treatments to be available to poorer populations.
II. THE PROBLEM WITH DRUG INNOVATION
As pharmaceutical companies continue to invent drugs and medications there has been a
continued focus on the rich which does not allow for maximum human flourishing as many
people are left without access to essential medicines. Pharmaceutical companies have focused
on the needs and wants of those living in wealthy companies while forgetting about those in
poorer nations. For instance, Sunder states that "The dominant law-and-economics approach
would rely on the market to spur creation but this leads to the appalling conclusion that drugs for
baldness must be more important than drugs for malaria because the former enjoy a multi-
billion-dollar market, while those who need the latter are too poor to offer much to save their
own lives" as the focus of pharmaceutical companies has been on developing lifestyle drugs. a0
This is because companies have more of an incentive to innovate where tlere is a wealthier
market with the ability to pay as this will result in the highest profits. Those in poorer nations
are more likely to have illness and death than those living in wealthier nations while 95% ofthe
people who have HIV reside in developing nations.al Moreover, according to the United
Nations Joint Programme on AIDS, lack of access to treatment has resulted in decreased survival
re Crook at 533.
40 Madhavi Sunder, From Goods to a G ood Life at29,2012.
4t Zita Lazzarini, Making Access to Pharmaceuticals a Reality: Legal Options Under TRIPS and the Case ofBrazil
at 105-106.
rates across poorer nations.42 Additionally, the inflated drug prices have caused poor nations to
be unable to afford treatment and drugs due to their significant mark up. Statistics have shown
that only 4.3%o of research and development for health was geared to the needs of poorer
nations.al Hopkins notes that:
"While developing countries form 80 percent ofthe market, new research is predominantly spent
on rich country concems... Tuberculosis, malaria, pneumonia and diarrhea account for 20 percent
of world disease and are rampant in underdeveloped regions of the world but obtained less than 1
percent ofthe funds allocated to health research in 2002...Developed countries should recognize
the role they have in ensuring that all individuals can exercise the right to public health no matter
their geographical or economic location. Signatories to the UDHR declaration have an
obligation to protect those beyond their own border. A global movement to shift the R&D focus
beyond the bottom line figures is necessary so as to incorporate neglected developing world
diseases."aa
Lazzaini notes that although high prices prevent poorer nations from access to
medications and other treatment, there are also numerous other barriers.as For instance, she
explains that the lack of public infrastructure is yet another barrier as there is a lack of testing,
counseling and overlooking of diseases.a6 She further notes that developing nations lack
clinicians and facilities who have the training and education necessary to give anti-retroviral
treatment and check on the progress of the patients.aT An improved infrastructure will allow for
a2 Lazzarini al106.
a3 Barry and Raworth, Access to Medicines and the Rhetoric of Responsibility. Ethics and lntemational Affairs at
57 .2002.
a Hopkins at l0l.
45 Lazzarini at ll4.
46 Lazzar],:,i at I | 4.
47 L?,Zar]Ji,i al ll4.
more doctors and better clinicians and facilities providing access and treatment so that humans
infected with HMAIDS have the opportunity to flourish.
Although there have been numerous developments and much progress with drug
inventions, the needs ofthe poorer nations have often been overlooked while the focus has been
on wealthier nations. This poses significant issues as the majority of poverty and illnesses lie in
the nations were pharmaceutical companies failed to aim their focus. For instance, Fisher and
Syed state in an article entitled, "Global Justice in Healthcare: Developing Drugs for the
Developing World" that "pharmaceutical firms concentrate their research and development
resources on diseases prevalent in Europe, the United States, and Japan 
- 
areas from which they
receive 90-95Yo of their revenues 
- 
and most of the diseases that afflict developing countries are
uncommon in those regions."48 Statistics have shown that "neglected diseases account for 16.40%
of the global disease burden. Yet, the portion ofglobal R & D expenditures that is comprised of
research directed at those diseases is in the range of 2-3%o. Only 1.5% of the total global burden
takes place in the developed world, where the pharmaceutical firms earn roughly 95% of their
revenue."4e Fisher and Syed have suggested that the amount of money spent on R&D should be
increased in the areas of medications and treatments for neglected diseases by using more
resources or by using some of the funds that are now being used on non-neglected diseases.50
This value based approach will allow for human beings globally to live healthier lives in order to
live to their best capabilities.
III. POVERTY AND ITS CONCERN
A. STOPPING THE SPREAD OF DISEASE
48 Fisher & Syed, Global Justice in Healthcare: Developing Drugs for the Developing World at 585, March 10,
2006. http://laweyiew.law.ucdavis.edu/issues/40/3/developing-drugs-for-developing-
word,/DavisVol40No3_Fisher.pdf.
4e Fisher and Syed at 612.
50 Fisher and Syed at 612-613.
Many of the diseases that affect poorer nations are excruciating both to those infected and
the family members where it is accepted that the likelihood of treatment and medication is slim
as these humans lack opportunity and well-being. However, these diseases also impact others
who may come into contact with infected individuals. In the article "Global Health Govemance"
the authors state that "Globalization has introduced or intensified national borders in their origin
or impact. Such risks may include emerging and reemerging infectious diseases, various
noncommunicable diseases (e.g. lung cancer, obesity, hypertension)."5r It is critical to note how
quickly illnesses spread impacting the entire community. Crook states that greater access to
medicine will allow for political, social and economic structures to be more stable in poor
nations and there should be focus on prevention and treatment of diseases.52 Fisher and Syed
state that there are negative extemalities with these diseases that stretch beyond the infected
individuals since those around them have a higher chance of getting the illness as well as
outbreaks need supra-national cooperative action.s3 Thus, we should strive for the full
development of humanity.
B. INCREASED TRADE AND MORE TRADING PARTNERS
Shifting the focus of pharmaceutical companies on the needs of poorer nations will not
only improve health and prevent the spread of disease yet it will also help promote economic
development by increased trade and allowing for a rise in the number of trading partners due to
an improvement in human flourishing. Fisher and Syed have explained that trade will help both
the North and the South as there will be more markets and more productivity with trading
51 Ri"h*d Dodgron, Kelley Lee and Nick Drager, Global Health Governance at 7, February 2002,
http://cgch.lshtm.ac. uk/globalhealthgovemance.pdf.
52 Crook at 538.
53 Fisher & Syed at 588-589.
partners as there are great links between increased health ofa nation and its development which
will also decrease chances of instability.s4
As diseases spread, the life expectancies in poorer countries that are significantly
impacted by these diseases will likely decline. This decline in life expectancies will certainly
affect labor and the ability to produce and trade goods. However, allowing poorer nations to
have access to medication and life-saving treatments while save lives allowing countries and its
citizens to be more productive being able to work and produce goods, and this will maximize
flourishing for citizens ofrich countries as well.
C. THE RIGHT TO LIFE
There is a right to life which includes a right to medication in intemational law as well as
in the South African Constitution and is consistent with a virtue ethics approach in promoting
maximum human flourishing globally. Although intemational law documents and treaties do not
specifically state that there is a right to pharmaceuticals, this right is founded in "the implications
of existing substantive provisions and in the special needs created by the curent
circumstances."ss For instance, the Universal Declaration of Human Rights states that there is a
"right to life, liberty and security of person... [and] no one shall arbitrarily be deprived of his
life."56 The Universal Declaration of Human fughts also establishes "the right to a standard of
living adequate for health and well-being of himself and his family [which] includes medical
care and necessary social services, and the right to security in... sickness, disability, widowhood,
old age or other lack of livelihood in circumstance beyond his control" as the UDHR has been
considered customary intemational law.57 The Intemational Covenant on Economic, Social, and
t4 Fisher and Syed at 589-590.
55 Lazzarini at 1l't .
56 Universal Declaration ofHuman Rights, art.3.
57 Universal Declaration ofHuman Rights, pmbl. 1948.
Cultural Rights (ICESCR) states in Article 12 that there is a right to "the highest attainable
standard of physical and mental health" requiring states to ensure for "the provision for the
reduction of the stillbirth-rate and of infant mortality and for the healthy development of the
child, the improvement of all aspects of environmental and industrial hygiene, the prevention,
treatment and control of epidemic, endemic occupational and other disease [and] the creation of
conditions which would assure to all medical service and medical attention in the event of
sickness."s8 Continually, the ICESCR creates the right to "enjoy the benefits of scientific
progress."se Moreover, the WTO requires the right of "enjoyment of the highest attainable
standard of health" which is considered 1o be a "fundamental right ofevery human being without
distinction ofrace, religion, political belief, economic or social condition."60
Crook states that the Committee on Economic, Social, and Cultural Rights discusses the
right to health in Article 15 which "recognizes the right of everyone to enjoy the benefits of
scientific progress and its applications and to benefit from the protection of the moral and
material interests resulting from any scientific, literary or artistic production of which he is the
author" "which could include access to break-through medications."6l Moreover, under the
Intemational Covenant on Civil and Political Rights (ICCPR), Article 6(1) states that "Every
human being has the inherent right to life. This right shall be protected by law. No one shall be
arbitrarily deprived ofhis life."62 This provision can be interpreted as the right to life consisting
of access to medication to allow for cure and prevent death from an illness that can be cured
through prescriptions. Another example of intemational law which requires a right to medication
58 lntemational Covenant on Economic, Social, and Cultural Rights, art. 12.1, C.A. Res.2200A(XXI) U.N. GAOR,
Supp. No. 16, at 49,1966.
5e /d., art. 15 $ l, !l b.
60 Constitution ofthe World Health organization, 1946.
6r Crook at 535.
62 International Covenant on Civil and Political Rights Art. 6(l), March 23, 1976.
i.,.tua", the Convention on Rights of the Child which states in Article 6 that "State parties
recognize that every child has the inherent right to life. States parties shall ensure to the
maximum extent possible the survival and development of the child."63 The aforementioned
treaties and customary international law express the right to life which is often at risk as a result
of intellectual property protection. As explained by Audrey Chapman, the human rights
approach focuses on protecting human dignity while balancing inventors interests which are
conditioned on assisting society's welfare.@
In addition to the right to life as expressed in international law (treaties and customary
international law), this right is also evident in domestic law such as in national constitutions. For
instance, our very own U.S. Constitution provides in the 14ft Amendment that "nor shall any
state deprive any person of life, liberty, or property."65 Moreover, in the South African
Constitution, Article 1l provides that "Everyone has the right to life."66 The South African
Constitution requires the government to take reasonable measures to allow for the right to access
health care services.6T The existence and application of a right to life is an example of a virtue
ethics approach which exists and works. The right to life encompassed in the constitutions of
various domestic nations demonstrates the right to access to pharmaceuticals in order to allow a
person to be treated and continue to live as individuals should be allowed to live well.
IV. RECOMMENDATIONS TO BETTER BALANCE PUBLIC HEALTH AND
INTELLECTUAL PROPERTY RIGHTS
63covenant on the Rights of the Child, Nov. 20, 1989, art. 6.
6a Audrey R. Chapman, Approaching Intellectual Property as a Human Right: Obligations Related to Article l5 (l)
(c) at note 61.
65 U.S. Const. Art. XIV.
66 South Africa Const. Art. XI.
67 Fix the patent laws at 3, http://www.tac.org.zalcommunitv/node/3241.
There have been some successful efforts to reduce poverty by permitting access to
medication which has focused on maximizing well-being. Cantrell points out that in South
Africa, Bristol-Meyers "agreed not to enforce a patent on an important AIDS/HIV medication,
permitting the South African govemment to purchase a lower-priced generic version."68 The
Millennium Development Goals were established to decrease poverty as part of the Millennium
Declaration.6e The Millennium Declaration was signed in September 2000 by 189 countries.T0
One of the United Nations Millennium Development Goals was to halve the people whose
income was under $1.25 aday in the years 1990 and20l5.7r The goal of halving the poverty
rates was met five years before the 2015 deadline.T2 In 2010, 700 million fewer people lived in
conditions of extreme poverty compared to in 1990.73
Unfortunately,1.2 billion people still live in poverty on a global scale and we must strive
for the full development of humanity.Ta Another United Nations Millennium Development Goal
was to cut the proportion of people who are undernourished by half by 2015.7s Across the world,
approximately 870 million people are malnourished while over 100 million children below five
years old are malnourished and underweight.T6 Krishnan states that "Millennium Development
Goals relating to HIV, tuberculosis and malaria, there were to have halted by 2015 and began to
reverse" and "according to the 2013 report, HIV remains the leading cause of death for women
of reproductive age globally with one woman dying every minute."77
68 Cantrell, at 437.
6e Vidya Krishnan, Countries meet poverty reduction goal, but trip on maternal health, July 4, 2013 at l.
70 lGishnan at l.
7r United Nations Millennium Development Goals at 1, http://www.un.org/millenniumgoals/poverty.shtml.
72 United Nations Millennium Development Goals at 1.
73 United Nations Millennium Development Goals at 1.
74 United Nations Millennium Development Goals at l.
7s United Nations Millennium Development Goals at 1.
76 United Nations Millennium Development Goals at l.
77 Krishnan at 2.
The purpose ofTRIPS is "reducing distortions and impediments to intemational trade and
ensuring that measures and procedures to enforce intellectual property rights do not themselves
become barriers to legitimate trade."7s However, intellectual property rights have become
barriers to trade especially in relation to poorer countries receiving access to medications and
treatments. Although the first line ARVs have declined in price from $10,000 per patient to $60
per patient there are only 4%o of people with second line ARV medications as 147o are needed
and the cost is 2.5 more expensive than the first ARV medications while the third line of ARV
drugs are lacking.ie The prices for the ARV medications are up to 35 times the amount of
nations who have greater generic competition.8o This lack of access hinders the achievement of
maximum human flourishing and there should be a focus on humans achieving their highest
potential.
Patent protection needs to be relaxed which will permit generic medications through
compulsory licenses and make treatment affordable to poorer nations which would allow for an
increase in human flourishing.8r At the same time, IP rights do need to be protected to the extent
necessary to sustain the "human flourishing" of the pharmaceutical companies. Compulsory
licensing has been defined by the WTO under TRIPS as follows: "when a govemment allows
someone else to produce the patented product or process without the consent ofthe patent owner.
It is one of the flexibilities on patent protection included in the TRIPS agreement."82 The WTO
continues to explain that these flexibilities have been incorporated into TRIPS since its adoption
78 Lazzarini at 109.
7e South Africa: Activists urge change to patent laws at 1, http://www.irinnews.or{report/94272lsouth-al}ica-
activists-urge-change-to-patent-laws.
80 In WHO, South defends use of TRTPS flexibilities for public health at l,
http://www.twnside.org.sg/title2,&ealth. info/20 I 4/hi I 40 I 05.htm.
8r Crook at 533.
82 World Trade Organization, Compulsory licensing of pharmaceuticals at 1, Sept. 2006.
http://www.wto.orgenglish,/tratop,e/trips e/public_health faLe.htm
in January 2005.83 Furthermore, the WTO states that for compulsory licensing to be applicable
there does not necessarily need to be an emergency as countries may determine when to grant
compulsory licenses.Ea
In clarifying numerous questions regarding compulsory licensing under TRIPS the WTO
explains:
"The TRIPS Agreement does list a number of conditions for issuing compulsory licenses, in
Article 31. In particular:
o Normally the person or company applying for a license has to have tried to negotiate a
voluntary license with the patent holder on reasonable commercial terms. Only if that
fails can a compulsory license be issued, and
. Even when a compulsory license has been issued, the patent owner has to receive
payment; the TRIPS Agreement says "the right holder shall be paid adequate
remuneration in the circumstances of each case, taking to account the economic value of
the authorization" but it does not define "adequate remuneration" or "economic value."
It cannot be given exclusively to licensees (e.g. the patent holder can continue to produce), and it
should be subject to legal review in the country."85
Additionally, TRIPS states that for "national emergencies", "other circumstances of
extreme urgency" or "public non-commercial use" (or "govemment use") or "anti-competitive
practices", a voluntary license is not required as this step can be skipped when time is crucial,
however; the patent owner must still be compensated.86 Adequate compensation is determined
83 World Trade Organization, Compulsory licensing of pharmaceuticals at l.
8a World Trade Organization, Compulsory licensing of pharmaceuticals at 1.
85 World Trade Organization, Compulsory licensing ofpharmaceuticals at l.
86 World Trade Organization, Compulsory licensing ofpharmaceuticals at l.
by officials in the concemed country while the patent owner may appeal.87 The TRIPS
agreement in Article 3l had previously stated that compulsory licenses were to be given for the
domestic market.88 However, at the Doha Conference in 2001, this provision was changed to
allow nations who were unable to create the pharmaceuticals to be able to get them at a lower
price from somewhere else if needed.8e The purpose of changing this provision was to create a
way to "allow generic copies made under compulsory licenses to be exported to countries that
lack production capacity" which will allow for well-being.eo
Similarly, according to the IP unit and members of the University of KwaZulu-Natal,
South Africa can specifically focus on generic medications in order to foster flourishing.
elFurthermore, compulsory licenses are not limited to emergencies and can be issued ifthere is a
shortage in supply to the market, "a desire to make fixed-dose combinations of medicines owned
by different right holders, dependent patent that is technologically important, desire to have
multiple sources of supply to prevent shortfalls of stock, and even a desire to promote local
production where there have been failures in technology transfer from right holders."e2 A focus
on generics will allow for human good and will allow individuals to live well.
Twenty-three nations have decided that they would not use compulsory licensing in
importing including: "Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany,
Greece, Iceland, Ireland, Italy, Japan, Luxembourg, Netherlands, New Zealand, Norway,
Portugal, Spain, Sweden, Switzerland, United Kingdom and the US. Since they joined the EU,
the list now includes 10 more: Czech Republic, Cyprus, Estonia, Hungary, Latvia, Lithuania,
87 World Trade Organization, Compulsory licensing ofpharmaceuticals at l.
E8 World Trade Organization, Compulsory Iicensing ofpharmaceuticals at 2.
8e World Trade Organization, Compulsory licensing of pharmaceuticals at 2.{ World Trade Organization, Compulsory licensing of pharmaceuticals at 2.9l Draft National Policy on Intellectual Property, Comments, Joint Submission, IP unit,20l3 at I l.
92 Draft National Policy on Intellectual Property, Comments, Joint Submission, Ip unit, 2013 at I l.
Malta, Poland, Slovak Republic and Slovenia."e3 Eleven other nations have stated that they
would only use compulsory licenses if there is a national emergency or "extreme urgency"
including: Hong Kong China, Israel, Korea, Kuwait, Macao China, Mexico, Qatar, Singapore,
Chinese Taipei, Turkey, and United Arab Emirates. While it is known that twenty-three nations
will not use compulsory licensing for importing and eleven others agreed only to use compulsory
licensing in extreme emergencies, it is evident that compulsory licenses for pharmaceuticals have
received serious criticism as interfering with intellectual property rights of the inventor. The
WTO stresses that all of the obstacles have not been removed as in order to use compulsory
licensing, exporting countries must also modiff their laws so that they are consistent with the
modifications made under TRIPS rather than simply allowing compulsory licensing mainly for
their domestic use.ea Presently, Norway, Canada, India and the EU have modified their laws to
be consistent with the changes under TRIPS.e5
In 1965, South Africa realizing that the IP laws at the time were not conducive to
flourishing, amended the Medicines Act in order to increase availability of medicines which has
been an effort towards improving well-being.e6 The nation's office for patents is in the
Companies and IP Commission which was created by the Companies Act and is responsible for
registering the patents.eT However, patent applications are not thoroughly examined.es The
Court for patents is the Commissioner of Patents who has authority under the Patents Act to
make rulings regarding infringements and compulsory licenses.ee Patents are maintained in the
e3 World Trade Organization, Compulsory licensing of pharmaceuticals at 2.
e4 World Trade Organization, Compulsory licensing of pharmaceuticals at 2.
e5 World Trade Organization, Compulsory licensing of pharmaceuticals at 2.
96 Park, Prabhala and Berger, United Nations Development Programme, Using Law to Accelerate Treatment Access
in South Africa at 22,2013.
e7 Park, Prabhala andBerger at22.
esPark, Prabhala andBerger at22.
ee Park, Prabhala and Berger at 24.
Patent Joumal that is now available electronically.loo Under the Patents Act, the process for
compulsory licensing is both long and expensive and must be brought before the Commissioner
in a judicial proceeding which can take three or even more years as the process has been
criticized for being unclear as the application goes to the commissioner, the judge of the High
Court which results in high costs due to arguments, adjoumments and undue delays.lol
However, TRIPS does not require the strict requirements adopted by South Africa in order to
obtain a compulsory license.ro2 It has been suggested that specific standards should be
implemented in order to help the Commissioner when deciding what is considered adequate in
terms of remuneration in order to avoid long litigation and high costs.lo3 By allowing for more
specificity in standards for compulsory licenses, generic companies will be able to better
"negotiate voluntary licenses on reasonable terms", produce more and provide greater access.lM
For instance, Canada caps the royalty rate to be 4Vo of the generic product's price.r05 According
to the United Nations Development Programme, "there may be cases in which the issuance of a
compulsory license is not a sufficient remedy for certain anti-competitive practices" and in those
cases patents should be able to be revoked in order to prevent abuses. 106 Presently, a
compulsory license for generic versions of the third line ARV is in dire need as there are no
generics for the third line of treatment currently available.r0T
Another suggestion is to allow parallel imports to allow for human good by wider access
to medicines. Parallel imports are defined by the World Health Organization as "imports of a
roo Park, Prabhala and Berger at 24.
rot Park, Prabhala and Berger at 24.
ro2 Park, Prabhala and Berger at 24.
Io3 Park, Prabhala and Berger at 24.
ro4 Park, Prabhala and Berger at 62.
ro5 Park, Prabhala and Berger at 63.
106 Park, Prabhala and Berger at 74.
ro7 Fix the patent laws at I .
patented or trademarked product from a country where it is already marketed."lo8 The World
Health Organization provides examples ofparallel importing and also explains the consequences
that will result from parallel importing as follows:
"In Mozambique 100 units of Bayer's ciprofloxacin (500mg) costs US$740, but in India
Bayer sells the same drug for US$15 (owing to local generic competition). Mozambique can
import the product from India without Bayer's consent. According to the theory of exhaustion of
intellectual property rights, the exclusive right of the patent holder to import the protected
product is exhausted, and thus ends, when the product is first launched on the market. When a
state or group of states applies this principle of exhaustion of intellectual property rights in a
given territory, parallel importation is authorized to all residents in the state in question. In a state
that does not recognize this principle, however, only the patent holder who has been registered
has the right to import the protected product... Parallel imports often takes place when there is
differential pricing of the same product - either brand-name or generic drugs - in different
markets (usually owing to local manufacturing costs or market conditions)... Parallel imports
can reduce the price of health products and pharmaceuticals by introducing competition.
However, they can also affect the negotiation of tiered pricing regimes with pharmaceutical
companies. Ifa private pharmaceutical company agrees to sell a product at a lower price in poor
countries, it will need some assurance that the cheaper product will not be imported back into its
rich country markets, undercutting its profits (product diversion)."r0e
Hopkins writes that parallel importing "[with] generic phamaceuticals, [has allowed]
members of Kenya's non-profit sector [to] successfully lower the cost of anti-retroviral triple
r08 World Health Organization, Parallel lmports at l, http://www.who.invtrade/glossary/story070len].
r@ World Health organization, Parallel lmports at 1 .
therapy drugs by 40%-65%...[ias parallel importing] endorses price equity in the market."rr0 As
pointed out by the World Health Organization if parallel importing is permitted, pharmaceutical
companies will be less likely to agree to tiered pricing which is another altemative. For instance,
Crook suggests that there should be different pricing structures according to a formula for
countries based on their per capita income, resources and the necessity for instantaneous
medication.l rr The strategy of pricing structures means that there would be price discrimination
in that pharmaceutical companies would offer medications at lower prices in some nations while
being able to keep higher prices in other nations.rr2 A pricing structure is not currently in place
as all countries must pay the same inflated price preventing poorer nations from having access to
treat diseases. For instance, Fisher and Syed have promoted changes to laws based on the
distribution of pharmaceutical innovations by allowing more governmental control over the
prices set for the medications while also allowing govemments to oversee how pharmaceutical
companies choose to invest and focus their research and development.ll3 For them, greater
govemmental control means greater access.
In South Africa, under the Minister of Health v. Treatment Action Campaign, it was ruled
in2002 that health care services consist of access to medicines.lla According to the wording of
the South African Constitution, the govemment must adopt a legal framework 10 allow for access
to essential medicines but also to take action in order to allow for a decline in drug prices in the
private sector while making sure that there is an adequate supply of the medication which may
rro Hopkins at 92.
rrr Crook at 547.
112 Lazzarini at 125.
rrr Fisher and Syed at 6?4.
114 Access to Essential Medicines, Health & Democracy at 445, h@://www .section27 .org.zalwp-
contenvuploads/20 I 0/04/Chapterl 4.pdf.
include direct price controls.rls Allowing for an adequate supply of medication through price
controls is consistent with allowing for human good. The govemment can implement direct
price controls by creating state guidelines for price-setting to allow manufacturers to create
prices and state factors to be relevant in setting prices.l16 Furthermore, the govemment can enact
legislation which prohibits high prices or can set direct price controls capping prices. r17
Another suggestion has been to provide public funding such as govemment subsidies in
order to help pharmaceutical companies by allowing them to have funds for continued research
and development in order to continue with medication developments.r r8 By implementing the
aforementioned suggestions, t}re concems of proponents of intellectual property rights vrill be
addressed since inventors will still be able to enjoy the "fruits of their labor" but would be
prevented from charging extremely inflated prices. This would allow poorer nations to be able to
purchase medications and treatments as pharmaceutical companies would also look to address
the concems and needs of poorer nations suffering from diseases while focusing their research
and development on these concems.l 19
Additionally, the Department of Trade and Industry suggested on September 4, 2013 that
South Africa can have national policies such as taxes on medicines to promote well-being.l2o A
further suggestion is to enact legislation to limit patents while allowing for generics in order to
promote competition in order to allow for lower prices.l2l The Department has also suggested
that distribution and manufacturing capacities be improved. r22 The Department notes that a
ll5 Access to Essential Medicines, Health & Democracy at 445.
l16 Access to Essential Medicines, Health & Democracy at 451.
ll? Access to Essential Medicines, Health & Democracy at 451.
rr8 Fisher and Syed at 674.
"e Fisher and Syed at 674.
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crurent issue in South Africa is that the nation does not thoroughly look at patent applications
and allows for companies to have numerous patents on the same medication even if they do not
qualifu as an "innovation" by definition which results in corporations to "extend the life of their
monopolies, block competition from generic manufacturers and charge inflated prices for
medicines in both the public and private sector."l23 Another suggestion by the Department is
that a solution would be to create a more strict definition for innovation and not allow patents
when current medications are combined or allowing patents for new uses of the patented
drugs.l2a In other words, South Africa should not grant patents for existing medications that
have very small chemical changes. Other recommendations in at a WHO Executive Board
Meeting in January 2014 ina Draft Resolution included limiting patents to only 20 years, having
a more thorough examination process for patents and focusing on parallel importation and
compulsory licenses.l2s South Africa grants numerous patents as 2,442 palents were granted in
2008 alone while countries such as Brazil only granted 278 patents from 2003'2008.t26
Furthermore, applying for patents is twenty times cheaper than the majority of patent offrces as
South Africa lacks a thorough patent examination process as this simplicity allows for more
patents and less access to medications due to the approved patents hindering humans from
achieving maximum potential by preventing individuals from living well with the ability to have
medicines.l2T
Further, the Department of Trade and Industry suggests this system could provide for
specific legislation to allow a right to healthcare under the South African Constitution.r28 The
r23 DTI'S draft lP policy lays foundation to preyent abusive patenting at 1,2013.
r24 DTI'S draft [P policy lays foundation to prevent abusive patenting at 1,2013.
r25 In WHO, South defends use ofTRIPS flexibilities for public health ar l.
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South African govemment has provided for the anti-retroviral treatment while also providing
counseling and testing which has had success.l2e South African President Ztma stated that l0
new hospitals were build or renovated and that the nation would begin "a new phase in the
implementation of the National Health Insurance progftlmme, which will extend quality
healthcare to the poor...[as there will also be] construction of 300 new health facilities, including
160 new clinics" as efforts to decrease the number of people with HIV/AIDS in South Africa.l30
Another suggestion is that in order to shift the focus of pharmaceutical companies
towards the needs of poorer nations, developed nations should create public-private partnerships
amongst pharmaceutical companies and governments in order to promote research and
development towards world diseases.l3l Public-private partnerships "would be based on
mechanisms of incentives where governments agree to purchase developed vaccines from firms
at a pre-negotiated price upon development, focusing on medicines in developing countries such
as malaria vaccines."l32
The eighth Millennium Development Goal was to create a global partnership for
development.r33 The World Health Organization stated the goal was to work with
pharmaceutical companies to allow for access to "affordable essential medicines in developing
countries."l3a 16" WHO reported that:
"Although nearly all countries publish an essential medicines list, the availability of medicines at
public-health facilities is often poor. Surveys conducted in over 50 low- and middle-income
r2e DTI's draft IP policy lays foundation to prevent abusive patenting at 1,2013.
r30 SA to expand HIV treatment programme at l.
r3r Hopkins at l0l.
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countries indicate that the availability of selected generic medicines at health facilities was only
38% in the public sector and 64% in the private sector. Lack of medicines in the public sector
forces patients to purchase medicines privately. In the private sector, generic medicines cost on
average six times more than their intemational reference price, while originator brands are
generally even more expensive. High prices often make medicines unaffordable, with common
treatments costing the lowest paid govemment worker several days' wages."l35
Furthermore, the WHO's approach in creating a global partnership for access to essential
medications includes certain activities such as:
. "WHO has developed global indicators for availability, price and affordability of
essential medicines.
. WHO/Health Action International pricing survey metlodology used in over 50 countries
has increased awareness ofthe pricing, affordability and availability of branded and
generic medicines in the public and private sectors.
. WHO provides pharmaceutical manufacturers with the information they need to produce
quality, safe, effective essential medicines to address leading public health concems.
. WHO offers essential capacity building and quality assurance monitoring for over 250
medicines to treat millions of patients with HIV/AIDS, tuberculosis and malaria, and with
reproductive health needs in developing countries."r36
Additionally, it is impo(ant that state and non-state actors are both involved in order to
achieve global justice with access to medication and treatment. According to Dodgson, Lee and
Drager, "liberal-intemationalist scholars view the purpose of global govemance as ultimately
moving towards a more liberal democratic global order in which states and IGOs have equal
roles.l37 Within such an order it is envisaged that power and influence will flow in a top-down
manner."l38 Continually, cosmopolitan democrats are proponents of diverse people within a
rr5 World Health Organization, MDG 8: develop a global partnership for development at l.
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137 Dodgron, Lee and Drager, at 16.
138 Dodg.or, Lee and Drager, at 16.
collaborative political community including IGOs and a larger intemational legal system.l3e
Despite the numerous approaches to global govemance, there is a need for a global framework as
suggested by Dodgson, Lee and Drager it is essential to establish leadership and authority with
health govemance globally as there must be sufficient resources "for health cooperation" as the
resources must be "distributed appropriately according to agreed priorities."lao These priorities
should be based upon the principle maximization of human flourishing.
V. CONCLUSION
Pharmaceutical companies have a tremendous impact on the global access to medicine.
Oftentimes, the focus of pharmaceutical companies is on the wants of the richer nations in order
to increase their profits. However, this has led to lack of access to medication in poorer nations
where humans have suffered and died as a result of lack of access to medications and treatments.
Pharmaceutical companies, govemments and international trade organizations have largely
maintained policies regarding IP rights which are based upon utilitarian economics. In other
words, they have promoted and sustained policies which purport to provide the greatest good to
the greatest number of people. The evidence outlined above shows that these policies do not
work this way. Indeed, in order to fulfill the utilitarian goal it must be scraped. The more
effective approach as outlined above is a virtue ethics one with a focus on striving for the full
development of humanity in order to allow for a human good. An example of this is the right to
life law which has been provided for in many international law treaties as well as intemational
customary law. This right includes the right to access to medications which will allow
individuals to live well. Some suggestions for allowing access to medication to poorer nations in
dire need of these treatments include compulsory licenses, public funding as well as a tiered-
139 Dodgron, Lee and Drager, at 16.
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p.i"ing .yr,"- which would make medications accessible to poorer nations while still providing
for intellectual property protection and revenues for pharmaceutical companies. Access to
medication to poorer nations will help prevent the spread of diseases in those nations and across
the globe and will at the same time be beneficially to the economy in that poorer nations will be
able to trade with other nations allowing for more products and trading partners. Pharmaceutical
companies should focus their resources and research and development more towards these poorer
nations in order to reduce illnesses in those nations as ethics require which will allow for humans
achieving their maximum potential.lal
rar Dodgson, Lee and Drager, at 20-22.
